BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 28244073)

  • 1. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
    Ingram JR; Burton T
    Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of patients with hidradenitis suppurativa.
    Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
    Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
    Arenbergerova M; Gkalpakiotis S; Arenberger P
    Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
    Yen CF; Huang YH; Chi CC
    Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab (Humira
    Gupta AK; Cernea M; Abramovits W; Vincent KD
    Skinmed; 2016; 14(4):291-294. PubMed ID: 27784520
    [No Abstract]   [Full Text] [Related]  

  • 8. Association and management of Crohn's disease plus hidradenitis suppurativa.
    dos Santos CH; Netto PO; Kawaguchi KY; Parreira Alves JA; de Alencar Souza VP; Reverdito S
    Inflamm Bowel Dis; 2012 Apr; 18(4):E801-2. PubMed ID: 21993924
    [No Abstract]   [Full Text] [Related]  

  • 9. Hidradenitis suppurativa and immune dysregulation.
    Jemec GB
    Br J Dermatol; 2012 Feb; 166(2):237-8. PubMed ID: 22268854
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hidradenitis suppurativa treated with infliximab].
    Obadia DL; Daxbacher EL; Jeunon T; Gripp AC
    An Bras Dermatol; 2009; 84(6):695-7. PubMed ID: 20191188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab (Humira°) and hidradenitis suppurativa.
    Prescrire Int; 2017 Apr; 26(181):94-96. PubMed ID: 30730659
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.
    Cline A; Pichardo RO
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
    Kanni T; Argyropoulou M; Spyridopoulos T; Pistiki A; Stecher M; Dinarello CA; Simard J; Giamarellos-Bourboulis EJ
    J Invest Dermatol; 2018 Apr; 138(4):795-801. PubMed ID: 29129600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?
    Martina E; Campanati A; Giuliodori K; Offidani A
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):21-23. PubMed ID: 28352932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
    Diamantova D; Lomickova I; Cetkovska P
    Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of recalcitrant hidradenitis suppurativa with ustekinumab.
    Sharon VR; Garcia MS; Bagheri S; Goodarzi H; Yang C; Ono Y; Maverakis E
    Acta Derm Venereol; 2012 May; 92(3):320-1. PubMed ID: 22101775
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.